GlassScriptPhysician profile
Valerie A Beard
NPI 1568431302
$3,523.58
in general payments reported to CMS, 2019-2025
30 companies · $755 in 2025
The $755 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $628 · 2020: $215 · 2022: $516 · 2023: $712 · 2024: $697 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,164.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $900.64 | 2022-2025 | Vraylar, Qulipta |
| Novo Nordisk INC | $593.93 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $280.68 | 2019-2024 | |
| Lilly USA, LLC | $272.78 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $200.62 | 2019-2025 | Airsupra |
| Axsome Therapeutics, INC. | $178.95 | 2024-2025 | Auvelity |
| Glaxosmithkline, LLC. | $152.93 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $112.69 | 2019-2025 | Veozah |
| Allergan, INC. | $83.08 | 2019-2020 | |
| Mylan Specialty L.P. | $74.41 | 2024 | Yupelri |
| Viatris Specialty LLC | $70.88 | 2025 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.27 | 2019-2023 | Xifaxan |
| Amgen INC. | $59.56 | 2023-2025 | Otezla, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.35 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.22 | 2022-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $42.89 | 2023-2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $41.08 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $34.28 | 2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $30.76 | 2020-2023 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $29.49 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $29.35 | 2020-2023 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $25.07 | 2025 | |
| Tris Pharma INC | $24.55 | 2023 | Dyanavel Xr |
| Phathom Pharmaceuticals, INC. | $23.67 | 2024-2025 | Voquezna |
| Abbott Laboratories | $17.20 | 2022 | |
| Supernus Pharmaceuticals, INC. | $15.51 | 2022 | |
| Sanofi Pasteur INC. | $15.39 | 2019 | |
| Currax Pharmaceuticals LLC | $14.71 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $14.46 | 2022 | |
| Amneal Pharmaceuticals LLC | $13.18 | 2023 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Valerie Beard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.